NDA 217927 · Solubiomix
Coxanto
Oxaprozin · Oral · Nonsteroidal Anti-inflammatory Drug
Last checked: Nov 20, 2026Latest source record: Nov 21, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2023
Oct 20, 2023
Approved uses
1
Original approval plus efficacy supplements
Registered trials
1
0 Phase 3, 0 recruiting
FAERS reports
886
491 serious, 31 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
Boxed warning
Warning: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS . WARNING: RISK OF SERIOUS CARDIOVASCULAR AND GASTROINTESTINAL EVENTS See full prescribing information for complete boxed warning. Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may occur early in treatment and may increase with duration of use ( 5.1) COXANTO is contraindicated in the setting of coronary artery bypass graft (CABG) surgery ( 4, 5.1) NSAIDs cause an increased risk of serious gastrointestinal (GI) adverse events including bleeding, ulceration, and perforation of the stomach or intestines, which can be fatal. These events can occur at any time during use and without warning symptoms. Elderly patients and patients with a prior history of peptic ulcer disease and/or GI...
What it is approved for
From the label in effect Dec 3, 2025.
OXAPROZIN is indicated: For relief of the signs and symptoms of osteoarthritis For relief of the signs and symptoms of rheumatoid arthritis For relief of the signs and symptoms of juvenile rheumatoid arthritis OXAPROZIN CAPSULES is a non-steroidal anti-inflammatory drug indicated for: Relief of signs and symptoms of Osteoarthritis (OA) (1) Relief of signs and symptoms of Rheumatoid Arthritis (RA) (1) Relief of signs and symptoms of Juvenile Rheumatoid Arthritis (JRA) (1)
Therapeutic areas: Pain and anesthesia
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- COXANTO · OXAPROZIN 300MG · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Oxaprozin" as an intervention, any sponsor and status, largest first.
Mochida Pharmaceutical Company, Ltd.Industry
NCT03350386 · 12 participants · Start Nov 2, 2017 · Primary completion Dec 5, 2017
Drug: FYU-981; Oxaprozin · For: Healthy
Sites: Hachiōji, Japan
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- chronic kidney disease82
- drug ineffective69
- pain68
- drug hypersensitivity61
- nausea60
- renal failure54
- acute kidney injury51
- arthralgia50
- dizziness49
- fatigue42
- headache38
- dyspnoea36
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 27 |
| 2005 | 55 |
| 2006 | 22 |
| 2007 | 13 |
| 2008 | 38 |
| 2009 | 35 |
| 2010 | 33 |
| 2011 | 36 |
| 2012 | 43 |
| 2013 | 54 |
| 2014 | 36 |
| 2015 | 55 |
| 2016 | 73 |
| 2017 | 53 |
| 2018 | 79 |
| 2019 | 82 |
| 2020 | 57 |
| 2021 | 21 |
| 2022 | 22 |
| 2023 | 24 |
| 2024 | 10 |
| 2025 | 11 |
| 2026 | 7 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- The uricosuric effect of oxaprozin in humans.
Goldfarb S, Walker BR, Agus ZS · J Clin Pharmacol 1985 · Clinical Trial, Comparative Study
- Oxaprozin versus diclofenac sodium in the treatment of ankylosing spondylitis.
Santo JE, Queiroz MV · J Int Med Res 1988 · Clinical Trial, Comparative Study
- Oxaprozin versus diclofenac in NSAID-refractory periarthritis pain of the shoulder.
Heller B, Tarricone R · Curr Med Res Opin 2004 · Clinical Trial, Comparative Study
- Oxaprozin: a once-daily treatment regimen in rheumatoid arthritis.
Reynolds WJ, Shaar SF, Buik A, et al. · J Rheumatol 1979 · Clinical Trial, Comparative Study
- [Oxaprozin versus diclofenac retard in treated of activated arthrosis].
Karbowski A, Schwitalle M, Eckardt A · Z Rheumatol 1998 · Clinical Trial, Comparative Study
- Oxaprozin cross-reactivity in three commercial immunoassays for benzodiazepines in urine.
Fraser AD, Howell P · J Anal Toxicol 1998 · Clinical Trial, Comparative Study
Sponsor: Solubiomix
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.